EpimAb Biotherapeutics (HK) Limited logo

EpimAb Biotherapeutics (HK) Limited

EpimAb Biotherapeutics is a privately owned R&D company based in Shanghai with a proprietary unique and efficient technology called FIT-Igë (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.epimab.com
Founded2015
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Room 205, Building 5, Jia Li Lue Rd 338 Zhangjiang High-Tech Park, 201203
Shanghai
China
Email
Contact Number
+49 15226107621

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/epimab-biotherapeutics-inc” connections=”true” suffix=””]

EpimAbs proprietary FIT-Ig (Fabs-In-Tandem) technology generates bi-specific antibodies by re-arranging the DNA sequences of two monoclonal antibodies into three constructs and co-expressing them in mammalian cells, when expressed together in a single mammalian cell, assemble properly to form a FIT-Ig in the correct structural orientation. These molecules have been characterized and demonstrated properties of conventional therapeutic monoclonal antibodies.

In April 2018, Zhejiang Teruisi Biopharmaceutical gain access to EpimAbs Fabs-In-Tandem Immunoglobulin (FIT-Igë) program FIT012/TRS008 to develop it for the Chinese market. Under the terms, EpimAb retains all commercial rights to the program outside of China. In return for commercialization rights in China, EpimAb received an upfront payment and total success-based milestones of up to US-$21 Mn, plus royalties. Further financial details were not disclosed.

In June 2016, EpimAb signed a multiple target agreement with Innovent Biologics for the development of bispecific antibodies. According to the terms, Innovent gains access to EpimAbs proprietary Fabs-In-Tandem Immunoglobulin platform to develop multiple bispecific antibodies for the Chinese market, including the right to out-license the developed programs outside of China. In return, EpimAb is eligible to receive an upfront payment and total milestones of up to USD 120 Mn, plus royalties.